Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Hansa Medical to Host Conference Call to Provide Year-End Report 2018 Business Update

Lund, Sweden, January 31, 2019 – Hansa Medical AB (publ) (Nasdaq Stockholm: HNSA) (“Hansa Medical” or the “Company”), under name change to Hansa Biopharma AB, a biopharmaceutical company focused on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that Hansa Medical will publish the 2018 Year-End Report on 8 February 2010, at 08:00AM CET, and that all interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 2:00PM CET. The event will be hosted by Hansa Medical’s CEO and President, Søren Tulstrup, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under Events & Webcast, and will also be made available online after the call. To participate in the telephone conference, please use the dial in details shown below:

SE: +46 856642705
UK: +44 3333009261
US: +1 6467224957

A link to audio cast can be found on the Hansa Medical website under Events & Webcasts or here: https://financialhearings.com/event/11683

The information was submitted for publication, through the agency of the contact person set out below at 08:15am CET on January 31, 2019.